Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT
Dana-Farber Cancer Institute
Paolo Tarantino; Nabihah Tayob; Guillermo Villacampa; Chau Dang; Denise A Yardley; Steven J Isakoff; Vicente Valero; Meredith Faggen; Therese Mulvey; Ron Bose; Douglas Weckstein; Antonio C Wolff; Katherine Reeder-Hayes; Hope S Rugo; Bhuvaneswari Ramaswamy; Dan Zuckerman; Lowell Hart; Vijayakrishna K Gadi; Michael Constantine; Kit Cheng; Audrey Merrill Garrett; P Kelly Marcom; Kathy Albain; Patricia DeFusco; Nadine Tung; Blair Ardman; Rita Nanda; Rachel C Jankowitz; Mothaffar Rimawi; Vandana Abramson; Paula R Pohlmann; Catherine Van Poznak; Andres Forero-Torres; Minetta C Liu; Kathryn J Ruddy; Adrienne G Waks; Michelle DeMeo; Harold J Burstein; Ann H Partridge; Patrizia Dell'Orto; Leila Russo; Emma Krause; Daniel J Newhouse; Busem Binboğa Kurt; Elizabeth A Mittendorf; Bryan Schneider; Aleix Prat; Eric P Winer; Ian E Krop; Sara M Tolaney; Consortium of the TBCRC Translational Investigators; TBCRC Translational Investigators